Hims & Hers Health (NYSE:HIMS) Given “Buy” Rating at BTIG Research

Hims & Hers Health (NYSE:HIMS)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a report released on Tuesday,Benzinga reports. They presently have a $85.00 price objective on the stock. BTIG Research’s price target points to a potential upside of 91.69% from the stock’s previous close.

Several other equities analysts have also issued reports on the company. Truist Financial dropped their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. KeyCorp assumed coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Bank of America raised their price objective on Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a report on Tuesday. Finally, Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health has an average rating of “Reduce” and a consensus price target of $43.58.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $44.34 on Tuesday. The firm has a market capitalization of $10.02 billion, a PE ratio of 55.43, a price-to-earnings-growth ratio of 3.15 and a beta of 2.25. The business’s fifty day moving average price is $51.42 and its 200 day moving average price is $50.73. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. Hims & Hers Health has a 12 month low of $19.15 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. The firm had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims & Hers Health’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, insider Michael Chi sold 900 shares of the stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the completion of the sale, the insider owned 291,439 shares in the company, valued at approximately $16,976,321.75. This represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 2,637 shares of the firm’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $50.10, for a total transaction of $132,113.70. Following the completion of the sale, the insider owned 158,493 shares of the company’s stock, valued at approximately $7,940,499.30. The trade was a 1.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 1,432,271 shares of company stock worth $74,229,585. Company insiders own 13.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. Signaturefd LLC increased its stake in shares of Hims & Hers Health by 17.7% during the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after purchasing an additional 388 shares in the last quarter. Ethic Inc. acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth approximately $348,000. Lake Hills Wealth Management LLC acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth approximately $277,000. Intellectus Partners LLC acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth approximately $3,043,000. Finally, Occidental Asset Management LLC acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth approximately $305,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.